Dutch COVID & Thrombosis Coalition

The Dutch COVID & Thrombosis Coalition tries to solve the questions related to COVID-19 associated thrombosis

[Dutch COVID & Thrombosis Coalition @CovidDutch]

DCTC assessed the incidence of thrombotic complications in COVID-19: in the second wave, the thrombotic complication rate remained high and comparable to the first wave, while mortality was reduced by 47% in the second wave: doi: 10.1016/j.thromres.2020.12.019 #ThrombosisResearch

[Dutch COVID & Thrombosis Coalition @CovidDutch]

The DCTC has shown that thrombotic complications are more likely to occur in hospitalized COVID-19 patients than in hospitalized patients with influenza. doi: 10.1002/rth2.12496 #RPTH

[Dutch COVID & Thrombosis Coalition @CovidDutch]

The DCTC has initiated a research program to answer current questions on the #COVID19 pathophysiology and best treatment of COVID19-associated thrombotic complications. Here, the design and main aims are summarized: https://t.co/LNTpa7PbR8 #RPTH

[Thrombosis Research @ThrombosisRese1]

Mortality was reduced by 47% in the second wave 🌊of #COVID19 , but the thrombotic complication rate remained high https://t.co/V8qUTFxKbJ

[RPTH @RPTHjournal]

With a clinical database of 5000 patients admitted to hospital with #COVID19 & 3000 biospecimens collected, a Dutch consortium hopes to answer many important questions to improve our understanding of the disease. These are highlighted here at #RPTH: https://t.co/oIYsng0W59

[RPTH @RPTHjournal]

A multidisciplinary team of experts in thrombosis, virology, & others have formed the Dutch COVID & Thrombosis Coalition. Here, they hope to answer important questions regarding #COVID19 pathophysiology & best treatments: https://t.co/oIYsng0W59 #RPTH

[Dutch COVID & Thrombosis Coalition @CovidDutch]

AstraZeneca vaccine & thrombotic events. DCTC experts on national tv.

https://t.co/goD8HMV9oU

[Dutch COVID & Thrombosis Coalition @CovidDutch]

We're off! The Dutch COVID & Thrombosis Coalition is online on Twitter now, to provide updates on our research.